209 related articles for article (PubMed ID: 15180540)
1. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.
Wang HG; Williams RE; Lin PF
Curr Pharm Des; 2004; 10(15):1785-93. PubMed ID: 15180540
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.
Guo Q; Ho HT; Dicker I; Fan L; Zhou N; Friborg J; Wang T; McAuliffe BV; Wang HG; Rose RE; Fang H; Scarnati HT; Langley DR; Meanwell NA; Abraham R; Colonno RJ; Lin PF
J Virol; 2003 Oct; 77(19):10528-36. PubMed ID: 12970437
[TBL] [Abstract][Full Text] [Related]
3. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.
Lin PF; Blair W; Wang T; Spicer T; Guo Q; Zhou N; Gong YF; Wang HG; Rose R; Yamanaka G; Robinson B; Li CB; Fridell R; Deminie C; Demers G; Yang Z; Zadjura L; Meanwell N; Colonno R
Proc Natl Acad Sci U S A; 2003 Sep; 100(19):11013-8. PubMed ID: 12930892
[TBL] [Abstract][Full Text] [Related]
4. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.
Vermeire K; Schols D
Expert Opin Investig Drugs; 2005 Oct; 14(10):1199-212. PubMed ID: 16185162
[TBL] [Abstract][Full Text] [Related]
6. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
Zhou N; Nowicka-Sans B; Zhang S; Fan L; Fang J; Fang H; Gong YF; Eggers B; Langley DR; Wang T; Kadow J; Grasela D; Hanna GJ; Alexander L; Colonno R; Krystal M; Lin PF
Antimicrob Agents Chemother; 2011 Feb; 55(2):729-37. PubMed ID: 21078948
[TBL] [Abstract][Full Text] [Related]
7. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
Ho HT; Fan L; Nowicka-Sans B; McAuliffe B; Li CB; Yamanaka G; Zhou N; Fang H; Dicker I; Dalterio R; Gong YF; Wang T; Yin Z; Ueda Y; Matiskella J; Kadow J; Clapham P; Robinson J; Colonno R; Lin PF
J Virol; 2006 Apr; 80(8):4017-25. PubMed ID: 16571818
[TBL] [Abstract][Full Text] [Related]
8. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.
Schön A; Madani N; Klein JC; Hubicki A; Ng D; Yang X; Smith AB; Sodroski J; Freire E
Biochemistry; 2006 Sep; 45(36):10973-80. PubMed ID: 16953583
[TBL] [Abstract][Full Text] [Related]
9. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
Zhou N; Nowicka-Sans B; McAuliffe B; Ray N; Eggers B; Fang H; Fan L; Healy M; Langley DR; Hwang C; Lataillade M; Hanna GJ; Krystal M
J Antimicrob Chemother; 2014 Mar; 69(3):573-81. PubMed ID: 24128669
[TBL] [Abstract][Full Text] [Related]
10. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.
Madani N; Perdigoto AL; Srinivasan K; Cox JM; Chruma JJ; LaLonde J; Head M; Smith AB; Sodroski JG
J Virol; 2004 Apr; 78(7):3742-52. PubMed ID: 15016894
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
Courter JR; Madani N; Sodroski J; Schön A; Freire E; Kwong PD; Hendrickson WA; Chaiken IM; LaLonde JM; Smith AB
Acc Chem Res; 2014 Apr; 47(4):1228-37. PubMed ID: 24502450
[TBL] [Abstract][Full Text] [Related]
12. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
13. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S
J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997
[TBL] [Abstract][Full Text] [Related]
14. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
Teixeira C; Serradji N; Maurel F; Barbault F
Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
[TBL] [Abstract][Full Text] [Related]
15. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
Ray N; Hwang C; Healy MD; Whitcomb J; Lataillade M; Wind-Rotolo M; Krystal M; Hanna GJ
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):7-15. PubMed ID: 23614999
[TBL] [Abstract][Full Text] [Related]
16. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
[TBL] [Abstract][Full Text] [Related]
17. Role of curdlan sulfate in the binding of HIV-1 gp120 to CD4 molecules and the production of gp120-mediated TNF-alpha.
Takeda-Hirokawa N; Neoh LP; Akimoto H; Kaneko H; Hishikawa T; Sekigawa I; Hashimoto H; Hirose S; Murakami T; Yamamoto N; Mimura T; Kaneko Y
Microbiol Immunol; 1997; 41(9):741-5. PubMed ID: 9343827
[TBL] [Abstract][Full Text] [Related]
18. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
[TBL] [Abstract][Full Text] [Related]
20. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
